IL22 and fatty liver disease: These metabolic shifts ‌subsequently activate‌ AhR, driving the upregulation of IL-22 and muc2, Tjp-1α, claudin1, and occludin, thereby restoring the barrier function, alleviating chronic inflammation and improving hepatic steatosis.